CD3E
Overview
CD3E encodes the CD3 epsilon chain, an essential signaling component of the T-cell receptor (TCR) complex. Together with CD3D, CD3G, and CD247 (CD3 zeta), CD3E forms the CD3 signaling module that transduces antigen recognition by the TCR into intracellular activation cascades. CD3E is required for surface expression of the TCR-CD3 complex and serves as a marker of T-cell infiltration in tumor biopsies.
Alterations observed in the corpus
- CD3E was identified as a component of the TCR/co-stimulatory immunological synapse upregulated on-therapy (cycle 1 day 29) in melanoma patients receiving nivolumab (anti-PD-1), as part of a 695-gene DEG set enriched in the genomic-contraction phenotype (q < 0.10) and a broader 475-DEG pharmacologic on-therapy response (q < 0.20). PMID:29033130
Cancer types (linked)
- SKCM: On-therapy upregulation of CD3E alongside other TCR-complex and co-stimulatory genes in melanoma patients on nivolumab is consistent with increased T-cell infiltration and activation. The contraction-phenotype gene set, of which CD3E is a member, stratified survival in independent immunotherapy cohorts. PMID:29033130
Co-occurrence and mutual exclusivity
Therapeutic relevance
- Coordinated on-therapy induction of the CD3E-containing TCR complex gene set under nivolumab treatment provides transcriptomic evidence for anti-PD-1-mediated restoration of T-cell activation in the tumor microenvironment. PMID:29033130
Open questions
- Pre-therapy CD3E expression as a standalone predictive biomarker for anti-PD-1 response was not specifically reported. PMID:29033130
Sources
This page was processed by crosslinker on 2026-05-15.